Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment
暂无分享,去创建一个
[1] S. Ezzat,et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[2] S. Melmed,et al. Clinical, quality of life, and economic value of acromegaly disease control , 2011, Pituitary.
[3] H. Shih,et al. Radiation therapy in the management of pituitary adenomas. , 2011, The Journal of clinical endocrinology and metabolism.
[4] P. Chanson,et al. A consensus on criteria for cure of acromegaly. , 2010, The Journal of clinical endocrinology and metabolism.
[5] P. Stewart,et al. Mortality in patients with pituitary disease. , 2010, Endocrine reviews.
[6] J. Romijn,et al. Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. , 2010, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.
[7] W. Ludlam. Growth Hormone Deficiency after Treatment of Acromegaly: A Randomized, Placebo-Controlled Study of Growth Hormone Replacement , 2010 .
[8] M. Molitch,et al. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly , 2009, Pituitary.
[9] P. Chanson,et al. Pituitary tumours: acromegaly. , 2009, Best practice & research. Clinical endocrinology & metabolism.
[10] J. Loeffler,et al. Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. , 2009, The Journal of clinical endocrinology and metabolism.
[11] P. Chanson,et al. Guidelines for acromegaly management: an update. , 2009, The Journal of clinical endocrinology and metabolism.
[12] P. Chanson,et al. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. , 2009, The Journal of clinical endocrinology and metabolism.
[13] G. Arnaldi,et al. Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly , 2009, Journal of endocrinological investigation.
[14] H. Pfister,et al. Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age- and gender-matched controls. , 2009, European journal of endocrinology.
[15] W. Drake,et al. Successful use of weekly pegvisomant administration in patients with acromegaly. , 2008, European journal of endocrinology.
[16] R. K. Hutson,et al. Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy. , 2009, Journal of endocrinological investigation.
[17] X. Badia,et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. , 2009, The Journal of clinical endocrinology and metabolism.
[18] M. Davi’,et al. Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. , 2008, European journal of endocrinology.
[19] R. Murray,et al. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. , 2008, The Journal of clinical endocrinology and metabolism.
[20] T. Rokkas,et al. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. , 2008, World journal of gastroenterology.
[21] Hang Lee,et al. Changing patterns in diagnosis and therapy of acromegaly over two decades. , 2008, The Journal of clinical endocrinology and metabolism.
[22] N. Pouratian,et al. GAMMA KNIFE RADIOSURGERY FOR ACROMEGALY: OUTCOMES AFTER FAILED TRANSSPHENOIDAL SURGERY , 2008, Neurosurgery.
[23] J. Petit,et al. Proton stereotactic radiosurgery in management of persistent acromegaly. , 2007, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[24] P. Brown,et al. Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. , 2007, Journal of neurosurgery.
[25] P. Caron,et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa , 2007, Clinical endocrinology.
[26] J. Wardlaw,et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly , 2007, Clinical endocrinology.
[27] S. Melmed. Medical progress: Acromegaly. , 2006, The New England journal of medicine.
[28] Tien-Chun Chang,et al. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. , 2006, European journal of endocrinology.
[29] L. Niskanen,et al. Quality of life in treated patients with acromegaly. , 2006, The Journal of clinical endocrinology and metabolism.
[30] X. Badia,et al. Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. , 2006, European journal of endocrinology.
[31] P. Caron,et al. Effectiveness and tolerability of 3‐year lanreotide Autogel® treatment in patients with acromegaly , 2006, Clinical endocrinology.
[32] X. Badia,et al. Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. , 2005, The Journal of clinical endocrinology and metabolism.
[33] J. Romijn,et al. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. , 2005, The Journal of clinical endocrinology and metabolism.
[34] R. Fahlbusch,et al. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. , 2005, European journal of endocrinology.
[35] I. Holdaway. Treatment of Acromegaly , 2004, Hormone Research in Paediatrics.
[36] S. Ezzat,et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND TREATMENT OF ACROMEGALY , 2004 .
[37] J. Bruce,et al. Basal and Glucose-Suppressed GH Levels Less Than 1 μg/L in Newly Diagnosed Acromegaly , 2004, Pituitary.
[38] H. Rodbard,et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. , 2003, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[39] S. Melmed,et al. Pituitary tumor registry: a novel clinical resource. , 2000, The Journal of clinical endocrinology and metabolism.
[40] M. Molitch. Clinical manifestations of acromegaly. , 1992, Endocrinology and metabolism clinics of North America.
[41] H. Quabbe. [Treatment of acromegaly]. , 1982, Deutsche medizinische Wochenschrift.